16Dec 2022
Achievement of glycemic targets with weight loss and without hypoglycemia in type 2 diabetes with once‐weekly GIP and GLP‐1 receptor agonist tirzepatide: a post‐hoc analysis of the SURPASS‐1 to ‐5 studies

Achievement of glycemic targets with weight loss and without hypoglycemia in type 2 diabetes with once‐weekly GIP and GLP‐1 receptor agonist tirzepatide: a post‐hoc analysis of the SURPASS‐1 to ‐5 studies

To assess composite endpoints combining glycemic control (HbA1c <7.0%, ≤6.5%, or <5.7%) with weight loss (≥5%, ≥10%, or ≥15%) and without hypoglycemia with tirzepatide in type 2 diabetes (T2D). Data from the phase 3 SURPASS program were evaluated post hoc by trial. The proportions of participants achieving the composite endpoints were compared between tirzepatide and the respective comparator groups at week 40/52. Across the SURPASS‐1 to ‐5 clinical trials, more tirzepatide‐treated participants with T2D achieved clinically meaningful composite endpoints, which included reaching glycemic targets with various degrees of weight loss and without hypoglycemia, than those in the comparator groups.

  • #endo-diabetology

Like

Save

Share